According to the latest market research study released by Technavio, the global alopecia drugs market is expected to grow at a CAGR of more than 5% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global alopecia drugs market based on ROA:
Global alopecia drugs market share by ROA 2015
|
Topical |
70.03% |
|
Oral |
25.97% |
|
Injectable |
4% |
Source: Technavio
The top three revenue contributing ROA segments are discussed below:
Global topical alopecia drugs market
Topical drugs accounted for around 70% of the overall revenue generated by the global alopecia drugs market in 2015. The increased preference for topical drugs can be attributed to the reluctance among physicians to prescribe systemic treatments such as pills or another form of treatment that affects the entire system of the body as they might suppress the androgen levels of the body. The global topical alopecia drugs market is anticipated to grow at a moderate pace during the forecast period driven by the relatively less number of approved therapies along with the sparse pipeline.
“The use of regenerative medicine is an emerging treatment option for alopecia. These medicines help in the healing process by replacement or regeneration of the human cells, tissues or organs, and assist in establishing the normal function. Cell therapy and growth factor therapy are some of the regenerative techniques included in the treatment of alopecia,” says Sapna Jha, a lead analyst at Technavio for infectious and rare diseases.
Global oral alopecia drugs market
During 2015, oral alopecia drugs accounted for almost 30% of the overall revenue generated from the sales of alopecia drugs in the global market. The market for oral alopecia drugs is expected to showcase moderate growth during the forecast period owing to the approval of the drug finasteride and a thin pipeline.
Global injectable alopecia drugs market
Global injectable alopecia drugs market is growing at a slow pace due to its less uptake. The major hindrance here is the ROA, which largely results for poor patient adherence. The corticosteroids are directly injected into the bald patches with a frequency of every 4-6 weeks. Injectable alopecia drugs aren’t widely accepted as patients find it tough to stick to the treatment regimen even if it would give better results.
The top leading vendors operating in the alopecia drugs market are:
- GlaxoSmithKline
- Johnson & Johnson
- Merck
The other prominent vendors in the market include Aclaris Therapeutics, Actelion Pharmaceuticals, Almirall, AndroScience, Anterios, Aqua Pharmaceuticals, Astellas Pharma, Bayer HealthCare, BERG Health, BiologicsMD, BioPharmX, Celtaxsys, Cipher Pharmaceuticals, Concert Pharmaceuticals, Cosmo Pharmaceuticals, Dermira, Elorac, F. Hoffmann-La Roche, Foamix, Guthy-Renker, Helix BioMedix, Hygeia Therapeutics, Hyundai Pharm, Incyte, Kasiak Research, Kythera Biopharmaceuticals, Mylan, NovaLead Pharma, Novan, Oculus Innovative Sciences, Paratek Pharmaceuticals, Photocure, Polichem, Promius Pharma, Ranbaxy Laboratories, Reckitt Benckiser, Regience, Samumed, RepliCel, Skinvisible Pharmaceuticals, Teva Pharmaceutical, Versapharm, and XBiotech..
A more detailed analysis is available in the Technavio report titled, ‘Global Alopecia Drugs Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Hypertension Drugs Market 2016-2020
- COPD Drugs Market in China 2016-2020
- Global MRSA Drugs Market 2016-2020
- Global Epilepsy Drugs Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
